Overview

Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma

Status:
RECRUITING

Trial end date:
2026-12-30

Target enrollment:

Participant gender:

Summary

Evaluating the efficacy and safety of treatment with Tislelizumab in combination with S-1 in patients with high-risk recurrent intrahepatic cholangiocarcinoma after radical surgery

Phase:

PHASE2

Details

Lead Sponsor:

Anhui Provincial Hospital

Treatments:

S 1 (combination)